Director Dealings / Market Share Sale and Purchase

RNS Number : 3490L
Oxford Biomedica PLC
18 July 2017
 

 

 

 

 

 

 

Director Dealings / Market Share Sale and Purchase

 

Oxford, UK - 18 July 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 14 July 2017 James Miskin, Chief Technical Officer, exercised 930,000 options at 1p and sold all of the resulting shares at 8.1p.  Following this transaction he holds 7,104,836 options and no shares in the company.

 

The issued share capital of the Company is  3,094,999,848 1p ordinary shares.

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Financial and corporate communications enquiries:

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

Tel: +44 (0)20 3709 5700

 

 

Notes for editors

 

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCRPMRTMBIBMJR
UK 100